Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 USD | -5.52% | -5.00% | -24.00% |
May. 09 | Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 02 | Vor Bio Appoints Fouad Namouni to its Board of Directors | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 2M | Capitalization | 117M |
---|---|---|---|---|---|
Net income 2024 * | -118M | Net income 2025 * | -119M | EV / Sales 2024 * | - |
Net Debt 2024 * | 26.57M | Net cash position 2025 * | 29.75M | EV / Sales 2025 * | 43.5 x |
P/E ratio 2024 * |
-1.18
x | P/E ratio 2025 * |
-1.28
x | Employees | 168 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.84% |
1 day | -5.52% | ||
1 week | -5.00% | ||
Current month | -0.58% | ||
1 month | -13.20% | ||
3 months | -22.97% | ||
6 months | -2.84% | ||
Current year | -24.00% |
Managers | Title | Age | Since |
---|---|---|---|
Bob Ang
CEO | Chief Executive Officer | 49 | 19-08-06 |
Nathan Jorgensen
DFI | Director of Finance/CFO | 47 | 20-04-30 |
Chief Tech/Sci/R&D Officer | 51 | 20-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Lubner
BRD | Director/Board Member | 60 | 20-07-29 |
Matt Patterson
CHM | Chairman | 52 | 20-10-19 |
Bob Ang
CEO | Chief Executive Officer | 49 | 19-08-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 0 M€ | +3.63% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 1.71 | -5.52% | 249,883 |
24-05-09 | 1.81 | -2.16% | 283,913 |
24-05-08 | 1.85 | +5.11% | 564,003 |
24-05-07 | 1.76 | +0.57% | 576,854 |
24-05-06 | 1.75 | -2.78% | 129,704 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.00% | 117M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- VOR Stock